BacMam transduction technology combines the ability of baculoviruses to maintain and amplify large gene inserts with the desirable post-translational characteristics of proteins expressed in mammalian cell lines. Improved versions of BacMam expression vectors demonstrate increased transduction efficiencies and wider ranges of permissible, mammalian host cells. BacMam technology has been used successfully in the fields of cell-based assays for drug discovery and for imaging of subcellular structures and functions. The development of a large-scale platform for the transient expression of recombinant proteins using BacMam transduction would significantly improve the current transient transfection methodology. We report our initial results obtained using BacMam constructs expressing a humanized rIgG. Serum-free suspension cultures of HEK-293 and CHO-S cells were cotransduced with BacMam viruses at total multiplicity of infection ratios between 10 and 20. Purified yields of 18.9 mg/L were obtained for shake-flask cultures of HEK-293 cells under nonoptimized conditions. These results illustrate the potential of the BacMam system to produce significant quantities of recombinant proteins in mammalian host cells…
Tag: <span>bacmam</span>
The impact of viruses—in geopolitical human health issues, in the production of vaccines and recombinant proteins, and in gene therapy and cancer treatments—highlights the need for a better understanding of the systems that are dependent upon them. A primary barrier to recognizing the full potential of these life-saving biomedical approaches is the scarcity of analytical methods capable of providing biologically relevant information without hindering the pace of development and production. ViroCyt® is a Colorado-based biotechnology company with one overriding focus: Enabling the rapid and specific quantification of viruses and virus-related particles. The ViroCyt Virus Counter® was designed to meet this objective.